ESMO Media Releases

”Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.

The TAT (Targeted Anticancer Therapies) International Congress 2018 will take place in Paris, France where around 450 attendees from all over the world are expected to join what is renowned to be “the home of phase I in oncology.”

The TAT 2018 Honorary Award for cancer drug development has been granted to Professor Jean-Charles Soria, for his pioneering role in cancer drug development across molecular targeted agents, precision medicine, and immunotherapy.

The ESMO Sarcoma & GIST Symposium in Milan, Italy has seen a record attendance of almost 450 international experts gathered to discuss the latest developments in the management of this rare condition, representing less than 1% of all adult solid cancers.

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care in its leading scientific journal, Annals of Oncology today.

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

You are still on time to register as Press representative for the ESMO Immuno Oncology Congress 2017 to be held in Geneva, 7-10 December 2017.

Since its inauguration in 2015, ESMO Asia Congress has garnered attention and significant interest from cancer experts and researchers not only in Asia but around the world. This year, the Congress is endorsed by twenty-one oncology societies across Asia and has attracted close to 3000 participants. 

A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.